La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Virpax Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Virpax Pharmaceuticals..

Virpax Pharmaceuticals (OTC:VRPX) Azioni, Catena delle Opzioni

Virpax Pharmaceuticals

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals Inc

WIIM

GOOS

Canada Goose shares are trading higher following better-than-expected Q4 financial results.

The Company's second quarter and full year Fiscal 2026 guidance below assumes that the current level of tariffs on imports into the U.S. from China and other countries as of May 21, 2025 will stay in place for the remainder of the year. The Company's full year Fiscal 2026 guidance assumes that it can offset the significant incremental pressure it has experienced and continues to expect from tariffs.&nbsp;

News

Guidance

TJX Q2 Outlook Assumes Current Level Of Tariffs On Imports To US From China And Other Countries As Of May 21, 2025 Will Stay For Remainder Of The Year

TJX Companies shares are trading lower after the company issued soft Q2 guidance.

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) sees FY2025 sales of $24.000 million vs $23.97 million analyst estimate.

MDWD

MediWound Sees FY2025 Sales $24.000M vs $23.97M Est

Jefferies analyst David Chiaverini initiates coverage on Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) with a Buy rating and announces Price Target of $53.

Price Target

Initiation

Analyst Ratings

CATY

Jefferies Initiates Coverage On Cathay General with Buy Rating, Announces Price Target of $53

Second Quarter and Full Year Fiscal 2026 Outlook
The Company's second quarter and full year Fiscal 2026 guidance below assumes that the current level of tariffs on imports into the U.S. from China and other countries as of May 21, 2025 will stay in place for the remainder of the year. The Company's full year Fiscal 2026 guidance assumes that it can offset the significant incremental pressure it has experienced and continues to expect from tariffs.
For the second quarter of Fiscal 2026, the Company expects consolidated comparable sales to be up 2% to 3%. The Company is planning second quarter Fiscal 2026 pretax profit margin to be in the range of 10.4% to 10.5%, down 0.4 to 0.5 percentage points versus the prior year's 10.9%. The Company is planning second quarter Fiscal 2026 diluted earnings per share to be in the range of $.97 to $1.00, which would represent a 1% to 4% increase versus the prior year's $.96. The Company's second quarter Fiscal 2026 outlook includes an incremental negative impact from tariff costs on the merchandise it was committed to at the time additional tariffs were announced in March and April of 2025.
For the full year Fiscal 2026, the Company continues to expect consolidated comparable sales to be up 2% to 3%. The Company continues to plan full year Fiscal 2026 pretax profit margin to be in the range of 11.3% to 11.4%, down 0.1 to 0.2 percentage points versus the prior year's 11.5%. The Company continues to expect full year Fiscal 2026 diluted earnings per share to be in the range of $4.34 to $4.43, which would represent a 2% to 4% increase over the prior year's $4.26. For the full year Fiscal 2026, the Company is maintaining its assumption that unfavorable foreign currency exchange rates and transactional foreign exchange would have an approximately 0.2 percentage point negative impact to pretax profit margin and an approximately 3% negative impact to earnings per share growth.

TJX Companies Affirms FY2026 GAAP EPS Guidance of $4.34-$4.43 vs $4.49 Est

PRZO

ParaZero Technologies Announced A Follow-on Purchase Order For Its Innovative SafeAir M4 Parachute Recovery System From A Prominent Drone Technology Partner In Europe

<h2 class="wp-block-heading">Coronado Global Resources: Uncovering a Diamond in the Rough</h2>
As the search for 2025's breakout stocks heats up, one name in the often-overlooked coal sector keeps rising to the surface: Coronado Global Resources (ASX: CRN). At first glance, coal might seem like an unlikely candidate in a world obsessed with clean energy. But <a href="https://coronadoglobal.com/">Coronado</a> isn't your average coal company. Specializing in metallurgical coal-the lifeblood of steel production-it operates in a niche that's far less vulnerable to the environmental pressures battering thermal coal. Trading at just 17 cents per share, down significantly from its post-IPO highs, Coronado feels like a stock that's been unfairly punished. Could this be the speculative gem that delivers outsized returns in 2025? Let's dive into its story and find out.
<h2 class="wp-block-heading">The Coronado Edge: A Metallurgical Marvel</h2>
Coronado Global Resources, headquartered in Australia, is a focused player in the metallurgical coal market. Its crown jewel lies in Queensland's Bowen Basin, a world-class coal region, with additional operations in the United States. Producing 15.3 million tons in the 2024 financial year, with expectations of growth in 2025 driven by new projects, the company supplies premium products like Hard Coking Coal (HCC), alongside Semi-Hard/Semi-Soft Coking Coal and Pulverized Coal Injection (PCI) Coal-all critical for steelmaking.
What sets Coronado apart is its singular focus on metallurgical coal, which enjoys a unique position in the industry. While thermal coal, used for power generation, faces growing regulatory headwinds, metallurgical coal remains indispensable. In 2025, thermal coal prices hover around $94.75 per ton, but metallurgical coal commands $190 per ton, a premium that underscores the resilience of Coronado's market. With clients like China, the USA, and Japan's Nippon Steel, the company benefits from steady demand across global steel hubs. But Coronado's appeal goes beyond production-it's a story of financial grit and untapped potential.
<h2 class="wp-block-heading">Financial Fortitude: A Balance Sheet Built to Last</h2>
In an industry where debt can be a death knell, Coronado stands out for its financial discipline. For the full 2024 financial year, the company reported $2.51 billion in revenue, though it swung to a net loss of $108.9 million, down from a profit of $156.1 million the prior year. Its net debt stood at $85 million, a manageable figure given its operational scale.
While the net loss reflects challenges like falling coal prices and operational hurdles, Coronado's relatively low debt is a rarity in the coal sector, where high leverage often amplifies risks. This lean balance sheet gives it room to maneuver-whether that means funding growth projects or weathering price dips without breaking a sweat. It's the kind of stability that makes investors take notice, especially when the stock price tells a very different story.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="612" height="458" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1.jpg" alt="" class="wp-image-13152" style="width:558px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1.jpg 612w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1-300x225.jpg 300w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
<h2 class="wp-block-heading">From IPO Glory to Rock Bottom: What Happened?</h2>
When Coronado went public on the Australian Securities Exchange in 2018, raising $500 million, it was a coal industry darling. Shares soared to the $1.50-2.50 range, fueled by optimism about its metallurgical focus. But the years since have been brutal. The COVID-19 pandemic disrupted global markets, metallurgical coal prices softened in 2024, and a failed deal to sell a controlling stake to Swedish firm Seven shattered investor confidence. The result? A stock now trading at a mere 17 cents.
It's tempting to write Coronado off as a has-been, but that might be premature. Its production remains robust, its assets are top-tier, and the steep share price drop could reflect market overreaction rather than fundamental weakness. Some analysts predict a rebound to $1.50-2.50, suggesting a potential 9-15x return for patient investors. To understand the opportunity, though, we need to confront the challenges head-on.
<h2 class="wp-block-heading">Navigating 2024's Storms: A Tough Year in Review</h2>
Coronado didn't have an easy ride in 2024. It produced 15.3 million tons, but faced significant headwinds. Metallurgical coal prices weakened, with 2025 prices at around $190 per ton, down from peaks of $300 per ton in 2024. Fitch Ratings had forecast a further slide to $120 per ton by 2025, though current prices are holding above that level, signaling some market resilience. Higher taxes and royalties in Queensland added pressure, while technical issues at the Curragh complex drove up costs and crimped output. The collapsed "Seven" deal was the final blow, leaving investors wary.
From a technical perspective, the stock remains in a downtrend, signaling caution for would-be buyers. Jumping in now risks catching a falling knife. Yet, even in these dark clouds, there's a silver lining-Coronado is laying the groundwork for a brighter future.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="636" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-1024x636.png" alt="" class="wp-image-13155" style="width:614px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-1024x636.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-300x186.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-768x477.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Turnaround in the Making: Growth on the Horizon</h2>
Coronado isn't sitting idle. In December 2024, the company launched its Mammoth underground mine, a project set to boost production efficiency. Meanwhile, the Buchanan mine expansion in the USA promises to scale up output, with projections of up to 2.5 million additional tons per year once fully ramped up. With 300 million tons of reserves in the Bowen Basin, Coronado has over two decades of premium coal to mine, ensuring long-term relevance in a steel-hungry world.
The company is also sharpening its edge through cost optimization and market diversification, reducing reliance on any single region. If coal prices stabilize and these initiatives deliver, Coronado could be on the cusp of a renaissance. But how does it stack up against the industry's heavyweights?
<h2 class="wp-block-heading">Coronado vs. the Titans: Small but Mighty</h2>
With 15.3 million tons of production in 2024, Coronado is a pretty small, compared to giants like China Energy Investment (600+ million tons) or Coal India Limited (700+ million tons). Even Glencore (100 million tons) and BHP Group (40 million tons) surpass it in scale. Yet, size isn't everything. Coronado's metallurgical focus gives it an edge over diversified players, many of whom are exposed to the declining thermal coal market. In a world where steel remains king, Coronado's niche could be its greatest asset.
<h2 class="wp-block-heading">The Bottom Line: A High-Stakes Bet Worth Considering</h2>
So, why pick Coronado Global Resources for 2025? It's a high-risk, high-reward play that hinges on a few key factors. Its solid finances, premium assets, and upcoming projects paint a picture of a company with staying power. If metallurgical coal prices stabilize and Coronado's growth plans bear fruit, a share price recovery to $1.50-2.50 could transform it into a standout performer, offering 9-15x gains.
But the risks are real. Coal price volatility, regulatory pressures, and operational hiccups could keep the stock under pressure. Technical indicators urge caution, suggesting investors wait for a trend reversal before diving in. For those with the stomach for risk, though, Coronado represents a rare opportunity-a undervalued player in an essential industry, ready to reclaim its shine back again.

Equities

Long Ideas

Commodities

Global

Opinion

Markets

Trading Ideas

A Coal Stock Poised For A 2025 Comeback?

TJX Companies Sees Q2 GAAP EPS $0.97-$1.00 vs $1.03 Est

Bernstein analyst Peter Weed maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and lowers the price target from $229 to $225.

PANW

Bernstein Maintains Outperform on Palo Alto Networks, Lowers Price Target to $225

Bread Financial Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) ("Bread Financial" or the "Company") today announced it has commenced a cash tender offer (the "Tender Offer") to purchase up to $150.0 million (subject to increase, the "Tender Cap") aggregate principal amount of its 9.750% Senior Notes maturing March 2029 (the "Notes"). The Tender Offer is being made on the terms and subject to the conditions set forth in the Offer to Purchase, dated May 21, 2025 (as it may be amended or supplemented, the "Offer to Purchase").
The Tender Offer will expire at 5:00 p.m., New York City time, on June 20, 2025, unless extended or earlier terminated as described in the Offer to Purchase (such date and time, as they may be extended, the "Expiration Time"), with an early participation deadline of 5:00 p.m., New York City time, on June 4, 2025 (the "Early Participation Date"), unless extended or earlier terminated.
The total consideration payable for each $1,000 principal amount of Notes will be determined based on a modified "Dutch Auction" procedure. Holders of the Notes ("Holders") who validly tender (and do not validly withdraw) their Notes before 5:00 p.m., New York City time, on the Early Participation Date, and whose Notes are accepted for purchase by the Company, will be eligible to receive the "Total Consideration," which includes an "Early Participation Amount" of $50.00 for each $1,000 principal amount of the Notes validly tendered.&nbsp;
The Company may, but is not obligated to, following the Early Participation Date and prior to the Expiration Time, elect to accept the Notes validly tendered by Holders on or prior to the Early Participation Date, for settlement on such date or promptly thereafter (the "Early Payment Date"). If the Company elects to have an Early Payment Date, it is currently expected to be June 9, 2025, though it will issue a press release announcing the date selected as the Early Payment Date.&nbsp;
Holders who validly tender their Notes after the Early Participation Date and on or prior to the Expiration Time, and who have their Notes accepted for purchase by the Company, will not be eligible to receive the Early Participation Amount and will only receive the Total Consideration minus the Early Participation Amount (the "Tender Offer Consideration") on the final payment date (the "Final Payment Date"). The Final Payment Date is currently expected to occur on June 25, 2025.

Bread Financial Holdings Commences Cash Tender Offer To Purchase Up To $150M Aggregate Principal Amount Of 9.750% Senior Notes Maturing March 2029

Jefferies analyst David Chiaverini initiates coverage on BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) with a Hold rating and announces Price Target of $105.

BOKF

Jefferies Initiates Coverage On BOK Financial with Hold Rating, Announces Price Target of $105

Financing

Caliber Announced Today The Successful Closing Of A $22.5M Refinance For The Doubletree By Hilton Hotel In Tucson, Arizona

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.66) by 89.39 percent. This is a 82.05 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $3.96 million which missed the analyst consensus estimate of $5.20 million by 23.91 percent. This is a 20.33 percent decrease over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MediWound Q1 EPS $(0.07) Beats $(0.66) Estimate, Sales $3.96M Miss $5.20M Estimate

CIBC Asset Management Announced The Launch Of The New CIBC Income Advantage Fund And CIBC U.S. Dollar Income Advantage Fund

QIPT

Quipt Home Medical Corp. shares are trading higher after the company confirmed the receipt of an unsolicited acquisition proposal from Forager Capital Management for $3.10 per share.

Comparable Sales by Division
The Company's comparable sales by division for the first quarter of Fiscal 2026 and Fiscal 2025 were as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">First Quarter&nbsp; Comparable Sales1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">FY2026</td>
<td colspan="1" rowspan="1">FY2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Marmaxx (U.S.)2</td>
<td colspan="1" rowspan="1">+2%</td>
<td colspan="1" rowspan="1">+2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HomeGoods (U.S.)3</td>
<td colspan="1" rowspan="1">+4%</td>
<td colspan="1" rowspan="1">+4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX Canada</td>
<td colspan="1" rowspan="1">+5%</td>
<td colspan="1" rowspan="1">+4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX International (Europe &amp; Australia)4</td>
<td colspan="1" rowspan="1">+5%</td>
<td colspan="1" rowspan="1">+2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX</td>
<td colspan="1" rowspan="1">+3%</td>
<td colspan="1" rowspan="1">+3%</td>
</tr>
</tbody>
</table>
</figure>

TJX Companies Q1 Comparable Sales +3%, Marmaxx +2%, HomeGoods +4%, TJX Canada +5%, TJX International (Europe & Australia) +5%

Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#TSX">QIPT</a>), a U.S. based home medical equipment provider focused on end-to-end respiratory care, today announced that it has received an unsolicited non-binding and conditional and indicative proposal from Forager Capital Management, LLC ("FCM") to acquire 100% of the Company's issued and outstanding common shares at a price of $3.10 per common share (the "Non-Binding Proposal").
It is the Company's policy not to comment on unsolicited offers and is confirming its receipt of the Non-Binding Proposal only because Forager has made it public. As previously disclosed, the Company entered into a Non-Disclosure and Standstill Agreement (the "Agreement"), dated February 1, 2025, with Forager Fund, L.P. ("Forager Fund") and FCM (collectively, with Forager Fund, "Forager"). The Agreement provides that Forager, and other representatives of Forager will, for a period of six (6) months after the date of the Agreement, not directly or indirectly acquire (or propose or agree to acquire), by purchase or otherwise, any equity securities or assets of Quipt, or rights or options to acquire interests in any of Quipt's equity securities or assets (the "Standstill") without the prior advance approval in writing by the Board of Directors of the Company (the "Board"). The Agreement also provides for customary terms related to the non-disclosure and use of confidential information of Quipt. The Board did not provide Forager with any prior written approval for a waiver of the confidentiality provision or the Standstill provision relating to the issuance of the Non-Binding Proposal.
In consultation with its financial and legal advisors, the Board remains focused on the best long-term interests of the Company to drive sustainable value for its shareholders. The Company does not intend to comment further on the Non-Binding Proposal, unless it is required to do so in accordance with applicable law.

TSX:QIPT

Quipt Home Medical Receives Unsolicited Non-Binding, Conditional And Indicative Acquisition Proposal From Forager Capital Management At $3.10/Shr

The Trump administration has put a halt to a lawsuit against&nbsp;Southwest Airlines&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) that was initiated by the Biden administration over alleged persistent flight delays.
What Happened: A Southwest spokesperson <a href="https://www.foxbusiness.com/economy/trump-admin-drops-biden-era-southwest-airlines-lawsuit-over-delays?ref=biztoc.com">told </a>Fox Business that the company appreciated the Department of Transportation's decision to drop its lawsuit, adding that they believed it was the correct outcome in this case.
The lawsuit, filed during the final days of the Biden administration, accused Southwest Airlines of &#8220;illegally operating multiple chronically delayed flights and disrupting passengers' travel.&#8221; The two flights at the heart of the lawsuit were between Chicago Midway International Airport and Oakland, California and Baltimore and Cleveland.
The lawsuit claimed that the flights experienced chronic delays for five consecutive months, affecting 180 passengers between April and August 2022. The Biden administration also accused Southwest Airlines of &#8220;unfair, deceptive and anticompetitive&#8221; conduct by allegedly providing inaccurate departure and arrival times.
However, a spokesperson for Southwest Airlines told Fox Business that the flights in question took place during the COVID-19 pandemic, a period of unparalleled challenges for the industry. 
The Department of Transportation (DOT) now maintains that the lawsuit should never have been filed. &#8220;Southwest has remedied the underlying issues and USDOT will work with them fairly, not sue them for political gain,&#8221; according to a DOT spokesperson.
SEE ALSO: <a href="https://benzinga.com/markets/cryptocurrency/25/05/45510057/senate-crypto-bill-passes-key-vote-genius-act-moves-toward-final-passage" target="_blank" rel="noreferrer noopener">Senate Crypto Bill Passes Key Vote, GENIUS Act Moves Toward Final Passage &#8211; Benzinga</a>
Why It Matters: The lawsuit against Southwest Airlines came at a time when airlines were facing a challenging start to 2025, with concerns centered around consumer behavior, domestic capacity and the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44087114/airlines-face-a-rough-start-to-2025-full-service-carriers-hold-the-advantage-analyst">effects of reduced</a> government travel. 
Southwest Airlines had also reported a volatile first quarter, with an <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44990066/whats-going-on-with-southwest-airlines-stock-thursday">adjusted loss</a> of 13 cents per share, beating analysts' estimate of a loss of 18 cents per share. The lawsuit&#8217;s dismissal could provide some relief to the airline, which has been working to improve its operational reliability.
Benzinga's Edge Rankings place Southwest Airlines in the 74th percentile for momentum and the 67th percentile for value, reflecting its strong performance in both areas. Check the detailed report <a href="https://www.benzinga.com/quote/LUV">here</a>. 
Over the past one month, the shares of Southwest Airlines surged 35.19%.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/general/travel/25/05/45516390/top-us-airports-see-sharpest-drop-in-arrivals-as-business-government-and-tourist-travel-decline" target="_blank" rel="noreferrer noopener">Top US Airports See Sharpest Drop In Arrivals As Business, Government And Tourist Travel Decline</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Administration Halts Biden-Era Lawsuit Against Southwest Airlines Over Alleged Flight Delays

NLSP

NLS Pharmaceutics Announces That It Will Present New Preclinical Data On Mazindol Er At The 2025 Annual Meeting Of The American Society Of Clinical Psychopharmacology

Comments

Virpax Pharmaceuticals

Virpax Pharmaceuticals (VRPX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO